
EPIKoda and APME signed a memorandum of cooperation 12.10.2023
On the 12-th of October 2023 the Estonian Chamber of People with Disabilities (EPIKoda) and APME signed a memorandum of cooperation in the field of health system promotion strategy. The memorandum was signed by Mrs. Maarja Krais-Leosk, CEO of EPIKoda and Mr. Riho Tapfer, CEO of APME.
The memorandum has been developed, drawn up and approved in cooperation with EPIKoda and APME. The initial approach to cooperation includes defining joint projects and organizing annual patient education days. This cooperation will help to empower the voice of patients regarding ongoing EU pharma reform as well.
More about patient trainings organized by EPIKoda and APME in 2022-2023 here.

Patient education day on the topic of “Patients voice: informed patient and medicines safety?” 19.09.2023
APME, Estonian Chamber of Disabled People (EPIKoda) and NGO Estonian Inflammatory Bowel Disease Society organized on 19-th of September 2023 a third patient education day on the topic of “Patients voice: informed patient and medicines safety?”.
The event took place in EPIKoda facilities and online and can be seen here, the event had sign language and written interpretation.
As a representative of pharmaceutical manufacturers, Mrs. Maaja Ivask (Roche) made a presentation on the topic of “Medicine safety – joint responsibility”. The education day consisted also of Agency of Medicines view, patients view (positive and negative experience), pharmacist view (treatment regimens which include many medications and ensuring safety) etc.

Analysis “Preliminary analysis of the implementation of the electronic package leaflet (ePIL) in Estonia”
In April 2023 APME finished its analysis “Preliminary analysis of the implementation of the electronic package leaflet (ePIL) in Estonia”
The aim of the project was to carry out a preliminary analysis of the implementation of the electronic packaging information leaflet (ePIL) in Estonia, which consisted of the following activities: 1) mapping of the field in Europe – what models are used in different countries and what are the most important ongoing projects; 2) possible technical solutions – both based on the Estonian Medicines Register and the planned solution of the European Medicines Agency (EMA); 3) overview of legislation and standards; 4) mapping of expectations and needs of Estonian shareholders; 5) creation of a vision of a possible user-friendly visual solution. The project was initiated by The Association of Pharmaceutical Manufacturers in Estonia as a country
engagement project funded by EFPIA.
More about the ePIL analysis can be read here.